^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Hengrui’s HER2- Breast Cancer Combo Awarded Breakthrough Status

Published date:
04/03/2024
Excerpt:
...China-based Jiangsu Hengrui Medicine Co., Ltd was granted breakthrough therapy designation (BTD) for the treatment of HER2 negative breast cancer with gBRCA mutation in China.